For example, HER2-overexpressing breast cancers have demonstrated enrichment for APOBEC mutagenesis [14] and both HER2 positive and Triple Negative breast cancer subtypes exhibit reduced Fhit protein expression in most tumors [31]. This evidence concerns the gene FHIT and breast carcinoma.